Navigation Links
Roche announces FDA approval of HIV viral load test

PLEASANTON, Calif., July 2, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a new HIV viral load test has been approved by the United States Food and Drug Administration (FDA) and will be commercially available in  the US later this year. Like other innovative Roche HIV tests, this one targets two highly conserved regions of the HIV-1 genome and avoids any regions which are current drug targets, thus providing increased reliability as compared to other single target assays should a mutation occur.

"The approval of the Roche HIV test expands the availability to more laboratories, clinicians and patients," said Paul Brown, PhD, Head of Roche Molecular Diagnostics. "Roche is committed to developing new diagnostic tools such as this highly innovative HIV 'dual target' test to help improve the ability of physicians to monitor viral load and properly treat people living with HIV."

About this test

The COBAS® TaqMan® HIV-1 Test, v2.0  utilizes the FDA-approved High Pure System Viral Nucleic Acid Kit for manual specimen preparation and the COBAS® TaqMan® 48 Analyzer for automated amplification and detection.

About the dual-target test approach

Roche's dual-target approach for HIV viral load testing ensures enhanced reliability of results and increased confidence in assessing viral loads even in the face of the rapidly growing genetic diversity of HIV-1.[1],[2]   This approach targets two highly conserved regions of the HIV-1 genome and avoids any regions which are current drug targets, thus providing reliable test results even with rare mismatches in primer/probe binding sites and when mutations are present.  Since Roche first introduced this innovative dual-target approach for monitoring HIV-1 patients on antiretroviral therapy in 2008, over eight million tests have been performed worldwide on Roche fully automated real-time PCR platforms.

About HIV

According to the Centers for Disease Control and Prevention (CDC), an estimated 1.2 million persons were living with HIV infection in the United States at the end of 2010. Of those, 20% had undiagnosed HIV infections.[3]  Highly active antiretroviral treatment (HAART) and viral load tests that determine the amount of circulating HIV have contributed to a profound increase in life expectancy for people living with HIV.[4] 

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information:

All trademarks used or mentioned in this release are protected by law.

[1] Clark SA, Calef C, Mellors JW. Mutations in retroviral genes associated with drug resistance. HIV sequence database. Accessed August 29, 2008.

[2] Chequer-Fernandez SL, Rodrigues CA, Campos-Melo DL, Pilotto JH, Morgado MG. HIV-1 polymorphism: evaluation of its potential implication for the response to antiretroviral therapy of HIV-1 infected patients with prevalent subtypes in Rio de Janeiro, Brazil [abstract]. Presented at: 15th International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract MoPeC3442. Accessed August 19, 2008.

[3] Centers for Disease Control and Prevention. HIV Surveillance Report, 2010; vol. 22. Published March 2012. Accessed June 18, 2012.

[4] Lancet. Volume 372, Issue 9635, 26 July 2008-1 August 2008, Pages 293-299

For further information please contact Roche Molecular Systems at 888-545-2443

SOURCE Roche Molecular Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rochester Medical Introduces Magic3® Coude Tip Hydrophilic Intermittent Catheter
2. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
3. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
4. K-V Pharmaceutical Company Announces Notification from NYSE Regarding Listing Criteria
5. Talyst Announces AutoSplit Contract Pharmacy at 340B Coalition
6. KALO Announces Distribution Areas
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Medivir Announces an Interferon-Free Phase II Combination Trial With TMC435 and daclatasvir to Commence Shortly
9. Hanger, Inc. Announces Second Quarter 2012 Earnings Release Conference Call
10. ResMed Announces Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year-End 2012 Results
11. Marshall Edwards Announces Name Change to MEI Pharma ("MEIP")
Post Your Comments:
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Competitive Intelligence, ... --> ) has ... Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... PUNE, India , November 26, ... --> --> ... Research Report" and "Investigation Report on ... 2019 and 2021 forecasts data and ... library. . ...
(Date:11/25/2015)... 25, 2015 ... the "Global Brain Monitoring Devices Market ... --> ) has announced the ... Devices Market 2015-2019" report to their ... ( ) has announced the addition ...
Breaking Medicine Technology:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... filthy the toilets were," said an inventor from Hillside, N.J. "Many people catch ... seat cover so that individuals will always be protected from germs." , He ...
(Date:11/27/2015)... ... ... Herpes-only dating community in the world, revealed that over 50% of its members are under ... under the age of 50 – or 67% of the population - are infected with ... infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of the ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... prided itself for not only fulfilling the needs of advisers and clients but ... affordable price and providing top-tier customer service. However, there's always room for improvement, ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap ... Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health ... both STEMI and Sepsis conditions present in similar ways and require time-critical intervention to ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... Inevitably when ... Many customers choose to buy during the Black Friday and Cyber Monday ... don’t need to search the Internet high and low to find the best massage ...
Breaking Medicine News(10 mins):